GNG Electronics IPO Updates: Rs 460 crore public offer to open on July 23 - Check price band, allotment date and more

Motilal Oswal Investment Advisors, IIFL Capital Services, and JM Financial are serving as the book-running lead managers for the issue, while Bigshare Services has been appointed as the registrar. The company’s shares are scheduled to be listed on the stock exchanges on July 30.

Operating under the brand name "Electronics Bazaar," the company has an extensive presence across the entire refurbishment value chain—ranging from sourcing and refurbishing to sales, after-sales service, and warranty support. It focuses on refurbishing ICT (Information and Communication Technology) devices, including laptops, desktops, tablets, servers, premium smartphones, and mobile workstations.

The proceeds from the fresh issue will be used to repay outstanding debt, support working capital needs, and meet general corporate expenses.

GNG Electronics has set the IPO price band at Rs 225 to Rs 237 per share. Investors can bid for a minimum of one lot containing 63 equity shares and in multiples thereafter. At the upper price limit, the company’s market capitalisation exceeds Rs 2,700 crore. The issue includes a fresh share offering worth Rs 400 crore and an offer for sale (OFS) of 25.5 lakh shares by promoters, totaling Rs 460.43 crore.

GNG Electronics will open its initial public offering (IPO) on Wednesday, July 23, targeting Rs 460 crore to repay existing borrowings and fund general corporate needs. The announcement was made during a press conference held on Friday, July 18, where company executives also revealed the price band and other offering details.

Anthem Biosciences makes strong debut, lists at Rs 723 against IPO price of Rs 570

Anthem Biosciences is a technology-driven Contract Research, Development, and Manufacturing Organization (CRDMO) with end-to-end capabilities spanning drug discovery, development, and commercial manufacturing. As one of the few Indian CRDMOs offering expertise in both New Chemical Entities (NCEs) and New Biological Entities (NBEs), the company caters to a wide spectrum of global clients, from emerging biotech startups to established pharmaceutical giants across more than 44 countries. Its service offerings include the production of fermentation-based Active Pharmaceutical Ingredients (APIs), such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.

Shares of ICICI Bank Ltd, India's second-largest private lender, gained in trade on Monday, July 21, after investors and experts were positive of the bank's beat on net interest margins (NIMs) for the quarter ended June 30, 2025. ICICI Bank reported a 15 percent year-on-year increase in net profit to Rs 12,768.21 crore for the fiscal first quarter, beating analyst expectations. NII (net interest income), which are the difference between interest earned and interest expended, stood at Rs 21,634.46 crore for the June quarter, up 8.4 percent on-year. (Read More)

Anthem Biosciences reported strong financial performance with a 30% year-on-year increase in revenue from operations, reaching Rs 1,930 crore in FY25, up from Rs 1,483 crore in FY24. Net profit also rose by 23% YoY to Rs 451 crore, compared to Rs 367 crore in the previous fiscal. The company maintained a healthy EBITDA margin of 36.8% and recorded a Return on Net Worth (RoNW) of 20.8%. At the upper end of the IPO price band of Rs 570, Anthem Biosciences is valued at a market capitalisation of Rs 31,867 crore.

“Trading members of the Exchange are hereby informed that the equity shares of Anthem Biosciences Limited shall be listed and admitted to dealings on the Exchange in due course,” a notice on the BSE said.

India's largest private lender HDFC Bank's shares were in the green on Monday, July 21, after reporting a 12 percent jump in net profit for the quarter ended June 30, 2025. Brokerages rushed to hike their target prices on the bank, expecting stronger growth in the second half of the current fiscal year.HDFC Bank posted a standalone net profit of Rs 18,155 crore for the quarter ended June 2025, marking a 12 percent rise from Rs 16,175 crore in the same period last year. Interest income for the quarter came in at Rs 77,470 crore, reflecting a 6 percent increase over the previous year. (Read More)

JM Financial is serving as the book-running lead manager for the Anthem Biosciences IPO, with Kfin Technologies appointed as the registrar for the issue.

Shares of Reliance Industries Ltd (RIL) slipped in trade on Monday after the diversified conglomerate reported its earnings report for the quarter ended June 30, sparking bullish brokerage commentary. Reliance Industries reported a 77 percent gain in net profit for the June quarter to Rs 30,783 crore, driven by a one-time gain from divesting its stake in Asian Paints. Even after excluding the Rs 8,924 crore gain, profit was up 25 percent year-on-year, as against Rs 15,138 crore in the same quarter last year. (Read More)

RIL, HDFC Bank, ICICI Bank, JSW Steel, IDFC First Bank, Dr Reddys Labs, IRCON, Sona Comstar, Anthem Biosciences in focus on 21 July (Read More)

According to data from InvestorGain, the latest grey market premium (GMP) for Anthem Biosciences IPO stands at Rs 179 as of July 21, 2025, 08:22 AM. With the IPO price band capped at Rs 570, the estimated listing price is projected to be around Rs 749 per share. This implies an expected listing gain of approximately 31.40% per share.

Patel Chem Specialities Limited (PCSL) is set to launch its SME IPO on July 25, aiming to raise Rs 58.80 crore. The offering, which will close on July 29, comes with a price band of Rs 82 to Rs 84 per share. PCSL is engaged in the manufacturing and export of pharmaceutical excipients and specialty chemicals, catering to both domestic and international markets.

TSC India Limited, a provider of technical and certification services, is set to roll out its initial public offering (IPO) worth Rs 25.89 crore. The IPO will be a fresh issue, priced between Rs 68 and Rs 70 per share. Although engaged in technical services, TSC India also operates as a travel management firm, offering comprehensive air ticketing solutions. With a strong focus on the B2B and corporate segments, the company collaborates with airlines and travel agents to provide cost-effective travel options.

Monarch Surveyors is set to open its initial public offering (IPO) on July 22, aiming to raise Rs 93.75 crore through a fully fresh issue. The IPO comes with a price band of Rs 237 to Rs 250 per share. The company offers a broad spectrum of services, including topographic surveys, project management consultancy, design and engineering, geotechnical investigations, land acquisition support, GIS mapping, and feasibility studies.

Engineering parts maker Swastika Castal Limited is gearing up to launch its initial public offering (IPO) worth Rs 14.07 crore. The issue will be entirely a fresh offering, comprising over 21.64 lakh equity shares priced at Rs 65 apiece. Horizon Management Private Limited is serving as the lead manager for the IPO. Swastika Castal operates in the aluminum casting sector, catering to various industrial applications.

Savy Infra, a company engaged in real estate and infrastructure development, is set to open its Rs 69.98-crore IPO from July 21 to July 23. The price band for the issue has been fixed between Rs 114 and Rs 120 per share.

According to the red herring prospectus (RHP), the Shanti Gold International IPO will consist entirely of a fresh issue of 1,80,96,000 equity shares, with no offer-for-sale (OFS) component. The price band for the IPO is expected to be announced in the coming days. Choice Capital Advisors Pvt Ltd is acting as the book-running lead manager, while Bigshare Services Pvt Ltd will serve as the registrar for the issue.

As per the red herring prospectus (RHP), the Brigade Hotel Ventures IPO consists solely of a fresh issue amounting to Rs 759.60 crore, with no offer-for-sale (OFS) component. The IPO price band is expected to be announced in the coming days. JM Financial Ltd and ICICI Securities Ltd are acting as the lead managers to the issue, while KFin Technologies Ltd is the designated registrar.

GNG Electronics is set to launch its Rs 460-crore IPO, which includes a fresh issue of Rs 400 crore and an offer-for-sale (OFS) of 25.5 lakh equity shares by promoter-linked shareholders. The price band for the issue has been fixed between Rs 225 and Rs 237 per equity share, with a face value of Rs 2. According to the 1Lattice Report dated March 31, 2025, the company is the leading refurbisher of laptops and desktops in India and ranks among the top global refurbishers of ICT devices, with a strong footprint across India, the USA, Europe, Africa, and the UAE.

The Rs 700-crore IPO of IndiQube Spaces comprises a fresh issue worth Rs 650 crore and an offer-for-sale (OFS) of 21,09,704 equity shares by promoter shareholders. The price band for the IPO has been fixed between Rs 225 and Rs 237 per share, with a face value of Re 1. IndiQube Spaces Limited offers managed, sustainable, and technology-driven workplace solutions, aiming to redefine the traditional office experience for modern businesses.

This week is set to see heightened activity on the SME platforms, with five companies preparing to launch their IPOs. Savy Infra & Logistics and Swastika Castal are scheduled to open on Monday, July 21, 2025. Monarch Surveyors & Engineering Consultants will follow on Tuesday, July 22, while TSC India is set to hit the market on Wednesday, July 23. Patel Chem Specialities is expected to open its issue on Friday, July 25, 2025. In addition, two SME listings are on the horizon—Spunweb Nonwoven is set to debut on the BSE SME platform on July 21, while Monika Alcobev will list on the NSE SME platform on July 23.

With Anthem Biosciences' IPO set to list in just a few hours, the primary market remains abuzz with activity. Indiqube Spaces and GNG Electronics are gearing up to launch their IPOs on Wednesday, July 23, 2025. Brigade Hotel Ventures is slated to hit Dalal Street on Thursday, July 24, followed by the IPO of Shanti Gold International on Friday, July 25, 2025.

Harshal Dasani, Business Head at INVasset PMS, stated, "If the stock lists in line with grey market expectations and the company sustains its earnings momentum in the second quarter, Anthem could establish itself as a significant player in India’s growing biotech landscape."

Anthem is also engaged in the production of specialised fermentation-based Active Pharmaceutical Ingredients (APIs), such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.

Mahesh M. Ojha, AVP – Research & Business Development at Hensex Securities Pvt Ltd, noted that robust demand—particularly from institutional investors—could lead to a listing price around Rs 700 or even higher, marking a premium of 20–25% over the issue price. "Short-term investors might consider booking partial gains if the stock lists significantly above the offer price. Long-term investors should focus on monitoring margin performance, product innovation, and client acquisition trends," Ojha advised. He further suggested that those who missed the IPO should wait for the stock to stabilise post-listing before making an entry.

Narendra Solanki, Head of Fundamental Research (Investment Services) at Anand Rathi Shares and Stock Brokers, noted that based on annualised FY25 earnings, Anthem Biosciences is valued at a price-to-earnings (PE) ratio of 70.6 times. The company’s post-issue market capitalisation is estimated at Rs 31,867 crore. He added, “We believe the IPO is reasonably priced, backed by robust growth potential, industry-leading margins, and consistent profitability. Investors who received allotments may consider holding the stock for long-term gains.”

While short-term gains are likely, analysts caution that sustained performance will rely on margin stability, a strong innovation pipeline, and the company’s ability to scale its global client base.

Anthem Biosciences is a tech-enabled, integrated service provider in drug discovery, development, and manufacturing—covering both small molecules and biologics.

Market observers expect Anthem Biosciences shares to debut at a premium of up to 25 percent over the issue price, reflecting the company’s sound financials and growth prospects.

The IPO, open from July 14 to 16, saw overwhelming interest from investors, receiving bids 63.86 times the shares on offer—highlighting strong market confidence in the company.

Ahead of the IPO, the Bengaluru-based company secured Rs 1,016 crore from anchor investors, further reinforcing confidence in its business model and execution capabilities.

The public offering was valued at Rs 3,395 crore, with a price band set between Rs 540 and Rs 570 per share, attracting significant institutional and retail participation.

The firm stands out as one of the few companies offering end-to-end services across the pharmaceutical and biotech value chain, catering to both Contract Research Organizations (CROs) and Contract Research, Development, and Manufacturing Organisations (CRDMOs).

Anthem Biosciences is set to make its stock market debut today, July 21, after witnessing an enthusiastic response from investors during its initial public offering (IPO).